Cigna modified MM 0526 for Vitamin D testing, effective October 16, 2025. Here's what billing teams need to know before claims start denying.
Cigna Healthcare updated its Vitamin D testing coverage policy under MM 0526, affecting three CPT codes — 82306, 82652, and 0038U — used to bill serum Vitamin D testing across hundreds of covered diagnoses. The update changes the medical necessity criteria that govern when these tests are considered reimbursable. If your team bills Vitamin D testing for Cigna members, review your ICD-10 pairing practices now — this is not a policy you want to catch up with after the effective date of October 16, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Vitamin D Testing |
| Policy Code | MM 0526 |
| Change Type | Modified |
| Effective Date | October 16, 2025 |
| Impact Level | High |
| Specialties Affected | Primary care, endocrinology, nephrology, oncology, infectious disease, rheumatology, gastroenterology |
| Key Action | Audit all active Vitamin D billing for CPT 82306, 82652, and 0038U against updated ICD-10 criteria before October 16, 2025 |
Cigna Vitamin D Testing Coverage Criteria and Medical Necessity Requirements 2025
The Cigna Healthcare Vitamin D testing coverage policy under MM 0526 covers three tests when specific medical necessity criteria are met. Those three codes are CPT 82306 (25-hydroxy Vitamin D), CPT 82652 (1,25-dihydroxy Vitamin D), and CPT 0038U (Vitamin D, 25-hydroxy D2 and D3 by LC-MS/MS, serum microsample, quantitative).
The distinction between 82306 and 82652 matters more than most billing teams realize. CPT 82306 measures 25-hydroxy Vitamin D — the standard test for overall Vitamin D status. CPT 82652 measures 1,25-dihydroxy Vitamin D, the active form. The active form test has a narrower clinical use case. Billing 82652 when 82306 was the appropriate test is a fast path to a claim denial under this policy.
CPT 0038U is a proprietary lab test (PLA code) for Vitamin D testing by liquid chromatography-tandem mass spectrometry on a serum microsample. It's covered under the same medical necessity framework as 82306. If your lab bills this code, confirm your ICD-10 pairings meet the same criteria required for 82306.
All three codes are considered medically necessary when the patient's diagnosis falls within the covered ICD-10 code set. That set is extensive — 486 ICD-10-CM codes in total. It spans tuberculosis (A15–A19 ranges), hepatobiliary and pancreatic malignancies, lymphomas, and far beyond. The breadth of the list is actually useful — but it also means your team needs to match the right code precisely. A diagnosis that's one character off can trigger a denial.
Prior authorization requirements for this policy are not explicitly stated in the MM 0526 documentation as a universal requirement. That said, some Cigna plan types impose prior authorization at the plan level, separate from the coverage policy itself. If your patient population includes a significant share of Cigna fully-insured commercial members, check plan-level requirements before assuming PA isn't needed.
Coverage Indications at a Glance
| Indication | Status | Relevant CPT Codes | Notes |
|---|---|---|---|
| Active tuberculosis (pulmonary and extrapulmonary, A15–A19) | Covered | 82306, 82652, 0038U | Must match specific TB ICD-10 code |
| Hepatobiliary malignancies (C22–C24 range) | Covered | 82306, 82652, 0038U | Includes liver, gallbladder, bile duct |
| Pancreatic malignancies (C25 range) | Covered | 82306, 82652, 0038U | All subsite codes included |
| Non-follicular lymphoma (C83.80–C83.89) | Covered | 82306, 82652, 0038U | Full range covered |
| Other diagnoses within the 486-code ICD-10 set | Covered | 82306, 82652, 0038U | Verify exact code match |
| Routine screening without covered diagnosis | Not Covered | All three codes | Absence of qualifying ICD-10 = denial |
| Testing beyond supported clinical indication | Not Covered | All three codes | Medical necessity must be documented |
Cigna Vitamin D Testing Billing Guidelines and Action Items 2025
The real risk with MM 0526 is volume. Vitamin D testing is one of the most frequently billed lab panels in outpatient settings. Small errors in ICD-10 selection at scale become big write-offs fast. Here's what to do before October 16, 2025.
| # | Action Item |
|---|---|
| 1 | Pull your Vitamin D testing claims from the last 90 days. Run a report on all claims billed with CPT 82306, 82652, and 0038U against Cigna. Identify the ICD-10 codes your team is currently using. Compare them against the 486-code covered list under MM 0526. |
| 2 | Update your charge capture templates and order sets. If your EHR or lab ordering system has a default ICD-10 attached to Vitamin D tests, verify it maps to a covered diagnosis. A catch-all code that worked before October 16, 2025 may not survive the updated medical necessity criteria. |
| 3 | Separate 82306 from 82652 in your clinical documentation protocols. These are not interchangeable. CPT 82652 is appropriate for specific clinical scenarios — granulomatous disease, hypercalcemia, chronic kidney disease — where the active form matters. If your providers are ordering 82652 routinely, that's a claim denial waiting to happen. Flag this with your medical director now. |
| 4 | Confirm 0038U is billed with a qualifying ICD-10. This PLA code gets less scrutiny in charge capture audits because it's less familiar. Treat it exactly like 82306 for ICD-10 pairing purposes. The same criteria apply. |
| 5 | Check plan-level prior authorization requirements for your Cigna contracts. MM 0526 sets the coverage policy. Individual plan contracts may add PA requirements on top of that. Pull your Cigna payer contracts and confirm whether any of your plan types require prior auth for lab testing. If you're not sure how this applies to your payer mix, talk to your compliance officer before October 16, 2025. |
| 6 | Train your front-end staff on documentation. Vitamin D testing denials frequently trace back to a missing or incorrect diagnosis at order entry — not at claim submission. The fix starts with the ordering provider documenting the qualifying condition clearly in the chart. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vitamin D Testing Under MM 0526
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 82306 | CPT | Vitamin D; 25 hydroxy, includes fraction(s), if performed |
| 82652 | CPT | Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed |
| 0038U | CPT (PLA) | Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative |
Key ICD-10-CM Diagnosis Codes
The full covered list includes 486 ICD-10-CM codes. Below are the codes provided in the MM 0526 policy data. Verify your complete list against the full policy document.
| Code | Description |
|---|---|
| A15.0 | Tuberculosis of lung |
| A15.4 | Tuberculosis of intrathoracic lymph nodes |
| A15.5 | Tuberculosis of larynx, trachea and bronchus |
| A15.6 | Tuberculous pleurisy |
| A15.7 | Primary respiratory tuberculosis |
| A15.8 | Other respiratory tuberculosis |
| A15.9 | Respiratory tuberculosis unspecified |
| A17.0 | Tuberculous meningitis |
| A17.1 | Meningeal tuberculoma |
| A17.81 | Tuberculoma of brain and spinal cord |
| A17.82 | Tuberculous meningoencephalitis |
| A17.83 | Tuberculous neuritis |
| A17.89 | Other tuberculosis of nervous system |
| A17.9 | Tuberculosis of nervous system, unspecified |
| A18.01 | Tuberculosis of spine |
| A18.02 | Tuberculous arthritis of other joints |
| A18.03 | Tuberculosis of other bones |
| A18.09 | Other musculoskeletal tuberculosis |
| A18.10 | Tuberculosis of genitourinary system, unspecified |
| A18.11 | Tuberculosis of kidney and ureter |
| A18.12 | Tuberculosis of bladder |
| A18.13 | Tuberculosis of other urinary organs |
| A18.14 | Tuberculosis of prostate |
| A18.15 | Tuberculosis of other male genital organs |
| A18.16 | Tuberculosis of cervix |
| A18.17 | Tuberculous female pelvic inflammatory disease |
| A18.18 | Tuberculosis of other female genital organs |
| A18.2 | Tuberculous peripheral lymphadenopathy |
| A18.31 | Tuberculous peritonitis |
| A18.32 | Tuberculous enteritis |
| A18.39 | Retroperitoneal tuberculosis |
| A18.4 | Tuberculosis of skin and subcutaneous tissue |
| A18.50 | Tuberculosis of eye, unspecified |
| A18.51 | Tuberculous episcleritis |
| A18.52 | Tuberculous keratitis |
| A18.53 | Tuberculous chorioretinitis |
| A18.54 | Tuberculous iridocyclitis |
| A18.59 | Other tuberculosis of eye |
| A18.6 | Tuberculosis of (inner) (middle) ear |
| A18.7 | Tuberculosis of adrenal glands |
| A18.81 | Tuberculosis of thyroid gland |
| A18.82 | Tuberculosis of other endocrine glands |
| A18.83 | Tuberculosis of digestive tract organs, not elsewhere classified |
| A18.84 | Tuberculosis of heart |
| A18.85 | Tuberculosis of spleen |
| A18.89 | Tuberculosis of other sites |
| A19.0 | Acute miliary tuberculosis of a single specified site |
| A19.1 | Acute miliary tuberculosis of multiple sites |
| A19.2 | Acute miliary tuberculosis, unspecified |
| A19.8 | Other miliary tuberculosis |
| A19.9 | Miliary tuberculosis, unspecified |
| C22.0 | Liver cell carcinoma |
| C22.1 | Intrahepatic bile duct carcinoma |
| C22.2 | Hepatoblastoma |
| C22.3 | Angiosarcoma of liver |
| C22.4 | Other sarcomas of liver |
| C22.7 | Other specified carcinomas of liver |
| C22.8 | Malignant neoplasm of liver, primary, unspecified as to type |
| C22.9 | Malignant neoplasm of liver, not specified as primary or secondary |
| C23 | Malignant neoplasm of gallbladder |
| C24.0 | Malignant neoplasm of extrahepatic bile duct |
| C24.1 | Malignant neoplasm of ampulla of Vater |
| C24.8 | Malignant neoplasm of overlapping sites of biliary tract |
| C24.9 | Malignant neoplasm of biliary tract, unspecified |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
| C26.0 | Malignant neoplasm of intestinal tract, part unspecified |
| C26.1 | Malignant neoplasm of spleen |
| C26.9 | Malignant neoplasm of ill-defined sites within the digestive system |
| C83.80–C83.89 | Other non-follicular lymphoma |
The full covered ICD-10 list under MM 0526 contains 486 codes. The codes above represent the diagnoses published in the available policy data. Pull the complete code list from the full MM 0526 policy document before finalizing your charge capture updates.
Get the Full Picture for CPT 82306
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.